Diverse perspectives on science and medicine
The authors of a recent article in JAMA Internal Medicine “Physician Gender and Outcomes of Hospitalized Medicare Beneficiaries in the U.S.,” Yusuke Tsugawa, Anupam B. Jena, Jose F. Figueroa, E. John Orav, Daniel M. Blumenthal,
Claims are spreading across social media that a goal of zero suicides can be achieved by radically re-organizing resources in health systems and communities. Extraordinary claims require extraordinary evidence. I thoroughly searched for evidence backing
A chance to test your rules of thumb for quickly evaluating clinical trials of alternative or integrative medicine in prestigious journals. A chance to increase your understanding of the importance of well-defined control groups and
An extraordinary, must-read article is now available open access: Jureidini, JN, Amsterdam, JD, McHenry, LB. The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance. International Journal of Risk &
A recent article in JAMA: Psychiatry: Sun Y, Farzan F, Mulsant BH, Rajji TK, Fitzgerald PB, Barr MS, Downar J, Wong W, Blumberger DM, Daskalakis ZJ. Indicators for remission of suicidal ideation following magnetic seizure
Unwarranted claims that “modifiable” negative beliefs cause Alzheimer’s disease lead to blaming persons who develop Alzheimer’s disease for not having been more positive. Lesson: A source’s impressive credentials are no substitute for independent critical appraisal
John Ioannidis, the “scourge of sloppy science” has documented again and again that the safeguards being introduced into the biomedical literature against untrustworthy findings are usually ineffective. In Ioannidis’ most recent report , his group:
I ponder this question guided by Le Chavalier C. Auguste Dupin, the first fictional detective, before anyone was called “detective.” Articles reporting the PACE trial have extraordinary numbers of authors, acknowledgments, and institutional affiliations. A
Earlier decisions by the investigator group preclude valid long-term follow-up evaluation of CBT for chronic fatigue syndrome (CFS). At the outset, let me say that I’m skeptical whether we can hold the PACE investigators responsible